• Login
KindredBio
  • About
    • Background
    • KindredBio Leadership
    • Board of Directors
  • Technology
    • Veterinary Recombinant Biologics
    • Manufacturing Process
  • Products
    • Mirataz® (mirtazapine transdermal ointment)
      • Mirataz home
      • About Feline Weight Loss
      • Mechanism of Action
      • Efficacy
      • Safety
      • Dosing and Administration
      • Resources
      • Mirataz News
      • For Cat Owners
      • Frequently Asked Questions
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Pipeline
      • Pipeline
      • Zimeta™ (dipyrone)
      • epoCat™ (feline recombinant erythropoietin)
    • Corporate Governance
    • Stock Information
    • Financial Information
    • Investor Resources
  • News
    • Press Releases
  • Contact Us
    • Contact Us
    • Careers
  • Search
  • Menu
News
You are here: Home / News / Future Events / No Events Currently Scheduled

No Events Currently Scheduled

February 12, 2013/in Future Events /by Russell Radefeld
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Reddit
  • Share by Mail
/wp-content/uploads/2017/09/KindredBioHeader2017.png 0 0 Russell Radefeld /wp-content/uploads/2017/09/KindredBioHeader2017.png Russell Radefeld2013-02-12 22:25:522016-02-12 22:27:50No Events Currently Scheduled

KindredBio News

  • Event: Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results
  • Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results
  • Event: Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit
  • Event: Kindred Biosciences to Present at Barclays Global Healthcare Conference
  • Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference

News Archives

  • February 2019
  • January 2019
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • August 2015
  • May 2015
  • March 2015
  • December 2014
  • November 2014
  • August 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • December 2013
  • August 2013
  • July 2013
  • March 2013
  • February 2013
  • January 2013

News

  • Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial ResultsFebruary 19, 2019 - 8:44 am
  • Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare ConferenceFebruary 13, 2019 - 8:33 am
  • Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters’ Option to Purchase Additional SharesJanuary 23, 2019 - 4:13 pm

Events

  • Event: Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial ResultsFebruary 19, 2019 - 8:45 am
  • Event: Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health SummitFebruary 13, 2019 - 8:37 am
  • Event: Kindred Biosciences to Present at Barclays Global Healthcare ConferenceFebruary 13, 2019 - 8:35 am
$10.63 Stock is Up 0.01 (0.09%)
KIN (Common Stock)
Previous Close Volume
$10.62 108,935
Intraday High Intraday Low
$10.67 $10.51
52 Week High 52 Week Low
$15.75 $8.05
Exchange: NASDAQ CM

KindredBio proudly supports
Rabies Free Africa

© Copyright 2012-2019 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010 | Privacy Policy| Website Terms of Use| Forward Looking Statements
KindredBio Announces Filing of an Investigational New Animal Drug Application... KindredBio Announces the Filing of an INAD for Laminitis in Horses
Scroll to top